{"disease":{"id":"grade-2-oligodendroglioma","name":"Grade 2 oligodendroglioma","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"vorasidenib","indication_name":"Grade 2 oligodendroglioma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Voranigo","generic_name":"VORASIDENIB","company_name":"Servier","drug_phase":"marketed","molecular_target":"","drug_class":"Isocitrate Dehydrogenase 1 Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Voranigo works by blocking the activity of an enzyme called isocitrate dehydrogenase 1."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05303519","title":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":365,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT07286292","title":"Vorasidenib Study in Pediatric Participants With Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Institut de Recherches Internationales Servier (I.R.I.S.)","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}